After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The company might need something better to replace its ageing blockbuster.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
While Cogent joins the FGFR party.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Just when investors thought things couldn't get any worse, they do.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
